...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Integrated Pharmacy Research and Practice >Anticholinergic discontinuation and cognitive functions in patients with schizophrenia: a pharmacist–physician collaboration in the outpatient department
【24h】

Anticholinergic discontinuation and cognitive functions in patients with schizophrenia: a pharmacist–physician collaboration in the outpatient department

机译：精神分裂症患者的抗胆碱能停药和认知功能：门诊部的药剂师与医生合作

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Cognitive impairment is a core feature and shows the highest impact on functional outcome in patients with schizophrenia. There have been no previous studies investigating the role of the pharmacist in a multidisciplinary team on cognitive outcomes in patients with schizophrenia. Purpose: We evaluated the impact of pharmacist intervention on cognitive outcomes in patients with schizophrenia by focusing on anticholinergic discontinuation. Patients and methods: A prospective, open-label, randomized, controlled study was conducted. Patients with schizophrenia were randomly assigned to either the pharmacist intervention or usual care groups. In the pharmacist intervention group, the pharmacist identified drug-related problems (DRPs) and provided a pharmacotherapy suggestion, while there was no intervention in the usual care group. The primary outcome was mean change from baseline of executive function by using Wisconsin Card Sorting Test (WCST) perseverative errors within the pharmacist intervention group at week 12. Results: A total of 30 patients completed the study (13 in the pharmacist intervention group and 17 in the usual care group). WCST perseverative errors at the end of the study within the pharmacist intervention group improved significantly from baseline ( P =0.003). DRPs at week 12 were reduced by 85.19% and 9.76% in the pharmacist intervention and usual care groups, respectively. The most common intervention was the discontinuation of anticholinergics in patients without extrapyramidal side effects. Conclusion: Added-on pharmacist intervention in a multidisciplinary team could help to improve cognitive functions in patients with schizophrenia by reducing DRPs and optimizing the drug therapy regimen, especially for anticholinergic discontinuation.
机译：简介：认知障碍是精神分裂症患者的核心特征，对功能结局影响最大。以前没有研究研究该药师在多学科团队中对精神分裂症患者认知结局的作用。目的：我们通过重点研究抗胆碱能的中断，评估了药剂师干预对精神分裂症患者认知结局的影响。患者和方法：进行了一项前瞻性，开放标签，随机对照研究。精神分裂症患者被随机分配至药剂师干预组或常规护理组。在药剂师干预组中，药剂师确定了药物相关问题（DRP）并提供了药物治疗建议，而常规护理组没有干预。主要结局是在第12周时通过药剂师干预组使用威斯康星卡片分类测试（WCST）持续性错误，从执行功能的基线发生平均变化。结果：共有30名患者完成了研究（药剂师干预组中有13名患者完成了研究，而17名患者完成了研究在常规护理组中）。在研究结束时，药剂师干预组的WCST持久性错误较基线有显着改善（P = 0.003）。在药剂师干预组和常规护理组中，第12周的DRP分别降低了85.19％和9.76％。最常见的干预措施是在没有锥体束外副作用的患者中停用抗胆碱药。结论：在多学科团队中增加药剂师干预可以通过减少DRP和优化药物治疗方案（尤其是抗胆碱能停药）来改善精神分裂症患者的认知功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号